Who is sponsoring NCT04685915?

NCT04685915 is sponsored by Inhye Ahn.

What condition does NCT04685915 study?

NCT04685915 studies Chronic Lymphocytic Leukemia (CLL).

What drugs are being tested in NCT04685915?

Interventions: Ibrutinib, Copanlisib, Acalabrutinib.

What is the status of NCT04685915?

NCT04685915 is currently WITHDRAWN.

Last reviewed 2025-05-22 · How we verify

Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL

NCT04685915 PHASE2 WITHDRAWN

This research study is examining the effect of adding a fixed duration of copanlisib to ibrutinib or acalabrutinib in select participants who have been on ibrutinib or acalabrutinib for at least six months for relapsed/refractory chronic lymphocytic leukemia (CLL). The names of the study drugs involved in this study are: * Copanlisib * Ibrutinib * Acalabrutinib

Details

Lead sponsor	Inhye Ahn
Phase	PHASE2
Status	WITHDRAWN
Start date	Thu Feb 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Mar 01 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Chronic Lymphocytic Leukemia (CLL)

Interventions

Ibrutinib
Copanlisib
Acalabrutinib